APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global RNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025196 pages

Choose your research edition.

Industry ResearchRNA Vaccines Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA Vaccines Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal RNA Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA Vaccines Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA Vaccines Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global RNA Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for RNA Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of RNA Vaccines include Translate Bio, Tiba Biotechnology, Sangamo Therapeutics, Moderna Therapeutics, In-Cell-Art, Ethris, eTheRNA, CureVac and BioNTech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global RNA Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of RNA Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents RNA Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the RNA Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

RNA Vaccines Segment by Company

Translate Bio

Tiba Biotechnology

Sangamo Therapeutics

Moderna Therapeutics

In-Cell-Art

Ethris

eTheRNA

CureVac

BioNTech

Argos Therapeutics

RNA Vaccines Segment by Type

Individualized Cancer Treatment MRNA Vaccine

Infection Prevention MRNA Vaccine

Infectious Disease Treatment MRNA Vaccine

RNA Vaccines Segment by Application

Infectious Disease

Cancer

Other

RNA Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the RNA Vaccines market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of RNA Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of RNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of RNA Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. RNA Vaccines Industry Trends Table 2. RNA Vaccines Industry Drivers Table 3. RNA Vaccines Industry Opportunities and Challenges Table 4. RNA Vaccines Industry Restraints Table 5. Global RNA Vaccines Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global RNA Vaccines Revenue Market Share by Manufacturers (2021-2026) Table 7. Global RNA Vaccines Sales by Manufacturers (k units) & (2021-2026) Table 8. Global RNA Vaccines Sales Market Share by Manufacturers Table 9. Global RNA Vaccines Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global RNA Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global RNA Vaccines Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global RNA Vaccines Manufacturers, Product Type & Application Table 13. Global RNA Vaccines Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global RNA Vaccines by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Individualized Cancer Treatment MRNA Vaccine Table 17. Major Manufacturers of Infection Prevention MRNA Vaccine Table 18. Major Manufacturers of Infectious Disease Treatment MRNA Vaccine Table 19. Global RNA Vaccines Sales by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global RNA Vaccines Sales by Type (2021-2026) & (k units) Table 21. Global RNA Vaccines Sales by Type (2027-2032) & (k units) Table 22. Global RNA Vaccines Sales Market Share by Type (2021-2026) Table 23. Global RNA Vaccines Sales Market Share by Type (2027-2032) Table 24. Global RNA Vaccines Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 25. Global RNA Vaccines Revenue by Type (2021-2026) & (k units) Table 26. Global RNA Vaccines Revenue by Type (2027-2032) & (k units) Table 27. Global RNA Vaccines Revenue Market Share by Type (2021-2026) Table 28. Global RNA Vaccines Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Infectious Disease Table 30. Major Manufacturers of Cancer Table 31. Major Manufacturers of Other Table 32. Global RNA Vaccines Sales by Application 2021 VS 2025 VS 2032 (k units) Table 33. Global RNA Vaccines Sales by Application (2021-2026) & (k units) Table 34. Global RNA Vaccines Sales by Application (2027-2032) & (k units) Table 35. Global RNA Vaccines Sales Market Share by Application (2021-2026) Table 36. Global RNA Vaccines Sales Market Share by Application (2027-2032) Table 37. Global RNA Vaccines Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 38. Global RNA Vaccines Revenue by Application (2021-2026) & (k units) Table 39. Global RNA Vaccines Revenue by Application (2027-2032) & (k units) Table 40. Global RNA Vaccines Revenue Market Share by Application (2021-2026) Table 41. Global RNA Vaccines Revenue Market Share by Application (2027-2032) Table 42. Global RNA Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 43. Global RNA Vaccines Sales by Region (2021-2026) & (k units) Table 44. Global RNA Vaccines Sales Market Share by Region (2021-2026) Table 45. Global RNA Vaccines Sales Forecasted by Region (2027-2032) & (k units) Table 46. Global RNA Vaccines Sales Forecasted Market Share by Region (2027-2032) Table 47. North America RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 48. North America RNA Vaccines Sales by Country (2021-2026) & (k units) Table 49. North America RNA Vaccines Sales by Country (2027-2032) & (k units) Table 50. Europe RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 51. Europe RNA Vaccines Sales by Country (2021-2026) & (k units) Table 52. Europe RNA Vaccines Sales by Country (2027-2032) & (k units) Table 53. Asia Pacific RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Asia Pacific RNA Vaccines Sales by Country (2021-2026) & (k units) Table 55. Asia Pacific RNA Vaccines Sales by Country (2027-2032) & (k units) Table 56. South America, Middle East and Africa RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 57. South America, Middle East and Africa RNA Vaccines Sales by Country (2021-2026) & (k units) Table 58. South America, Middle East and Africa RNA Vaccines Sales by Country (2027-2032) & (k units) Table 59. Global RNA Vaccines Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global RNA Vaccines Revenue by Region (2021-2026) & (US$ Million) Table 61. Global RNA Vaccines Revenue by Region (2027-2032) & (US$ Million) Table 62. Global RNA Vaccines Revenue Market Share by Region (2021-2026) Table 63. Global RNA Vaccines Revenue Market Share by Region (2027-2032) Table 64. Translate Bio Company Information Table 65. Translate Bio Business Overview Table 66. Translate Bio RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Translate Bio RNA Vaccines Product Portfolio Table 68. Translate Bio Recent Development Table 69. Tiba Biotechnology Company Information Table 70. Tiba Biotechnology Business Overview Table 71. Tiba Biotechnology RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Tiba Biotechnology RNA Vaccines Product Portfolio Table 73. Tiba Biotechnology Recent Development Table 74. Sangamo Therapeutics Company Information Table 75. Sangamo Therapeutics Business Overview Table 76. Sangamo Therapeutics RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sangamo Therapeutics RNA Vaccines Product Portfolio Table 78. Sangamo Therapeutics Recent Development Table 79. Moderna Therapeutics Company Information Table 80. Moderna Therapeutics Business Overview Table 81. Moderna Therapeutics RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Moderna Therapeutics RNA Vaccines Product Portfolio Table 83. Moderna Therapeutics Recent Development Table 84. In-Cell-Art Company Information Table 85. In-Cell-Art Business Overview Table 86. In-Cell-Art RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. In-Cell-Art RNA Vaccines Product Portfolio Table 88. In-Cell-Art Recent Development Table 89. Ethris Company Information Table 90. Ethris Business Overview Table 91. Ethris RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Ethris RNA Vaccines Product Portfolio Table 93. Ethris Recent Development Table 94. eTheRNA Company Information Table 95. eTheRNA Business Overview Table 96. eTheRNA RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. eTheRNA RNA Vaccines Product Portfolio Table 98. eTheRNA Recent Development Table 99. CureVac Company Information Table 100. CureVac Business Overview Table 101. CureVac RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. CureVac RNA Vaccines Product Portfolio Table 103. CureVac Recent Development Table 104. BioNTech Company Information Table 105. BioNTech Business Overview Table 106. BioNTech RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. BioNTech RNA Vaccines Product Portfolio Table 108. BioNTech Recent Development Table 109. Argos Therapeutics Company Information Table 110. Argos Therapeutics Business Overview Table 111. Argos Therapeutics RNA Vaccines Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Argos Therapeutics RNA Vaccines Product Portfolio Table 113. Argos Therapeutics Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. RNA Vaccines Distributors List Table 117. RNA Vaccines Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. RNA Vaccines Product Image Figure 2. Global RNA Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global RNA Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global RNA Vaccines Sales (2021-2032) & (k units) Figure 5. Global RNA Vaccines Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 RNA Vaccines Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Individualized Cancer Treatment MRNA Vaccine Image Figure 9. Infection Prevention MRNA Vaccine Image Figure 10. Infectious Disease Treatment MRNA Vaccine Image Figure 11. Global RNA Vaccines Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global RNA Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global RNA Vaccines Sales Market Share by Type (2021-2032) Figure 14. Global RNA Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 15. Global RNA Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global RNA Vaccines Revenue Market Share by Type (2021-2032) Figure 17. Infectious Disease Image Figure 18. Cancer Image Figure 19. Other Image Figure 20. Global RNA Vaccines Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 21. Global RNA Vaccines Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global RNA Vaccines Sales Market Share by Application (2021-2032) Figure 23. Global RNA Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 24. Global RNA Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global RNA Vaccines Revenue Market Share by Application (2021-2032) Figure 26. North America RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 27. North America RNA Vaccines Sales Market Share by Country (2021-2032) Figure 28. U.S. RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 29. Canada RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 30. Mexico RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 31. Europe RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 32. Europe RNA Vaccines Sales Market Share by Country (2021-2032) Figure 33. Germany RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 34. France RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 35. U.K. RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 36. Italy RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 37. Netherlands RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 38. Asia Pacific RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 39. Asia Pacific RNA Vaccines Sales Market Share by Country (2021-2032) Figure 40. China RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 41. Japan RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 42. South Korea RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 43. Southeast Asia RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 44. India RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 45. Australia RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 46. South America, Middle East and Africa RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 47. South America, Middle East and Africa RNA Vaccines Sales Market Share by Country (2021-2032) Figure 48. Brazil RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 49. South Africa RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 50. Saudi Arabia RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 51. Turkey RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 52. Argentina RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 53. UAE RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 54. Egypt RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 55. Chile RNA Vaccines Sales and Growth Rate (2021-2032) & (k units) Figure 56. Global RNA Vaccines Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global RNA Vaccines Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America RNA Vaccines Revenue (2021-2032) & (US$ Million) Figure 59. North America RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe RNA Vaccines Revenue (2021-2032) & (US$ Million) Figure 61. Europe RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific RNA Vaccines Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa RNA Vaccines Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. RNA Vaccines Value Chain Figure 67. Manufacturing Cost Structure Figure 68. RNA Vaccines Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Individualized Cancer Treatment MRNA Vaccine
  • Infection Prevention MRNA Vaccine
  • Infectious Disease Treatment MRNA Vaccine
Applications
  • Infectious Disease
  • Cancer
  • Other
Companies covered
  • Translate Bio
  • Tiba Biotechnology
  • Sangamo Therapeutics
  • Moderna Therapeutics
  • In-Cell-Art
  • Ethris
  • eTheRNA
  • CureVac
  • BioNTech
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global RNA Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global RNA Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global RNA Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global RNA Vaccines Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global RNA Vaccines Market Dynamics
  1. 2.1 RNA Vaccines Industry Trends
  2. 2.2 RNA Vaccines Industry Drivers
  3. 2.3 RNA Vaccines Industry Opportunities and Challenges
  4. 2.4 RNA Vaccines Industry Restraints
3 RNA Vaccines Market by Manufacturers
  1. 3.1 Global RNA Vaccines Revenue by Manufacturers (2021-2026)
  2. 3.2 Global RNA Vaccines Sales by Manufacturers (2021-2026)
  3. 3.3 Global RNA Vaccines Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global RNA Vaccines Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global RNA Vaccines Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global RNA Vaccines Manufacturers, Product Type & Application
  7. 3.7 Global RNA Vaccines Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global RNA Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 RNA Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 RNA Vaccines Tier 1, Tier 2, and Tier 3
4 RNA Vaccines Market by Type
  1. 4.1 RNA Vaccines Type Introduction
  2. 4.1.1 Individualized Cancer Treatment MRNA Vaccine
  3. 4.1.2 Infection Prevention MRNA Vaccine
  4. 4.1.3 Infectious Disease Treatment MRNA Vaccine
  5. 4.2 Global RNA Vaccines Sales by Type
  6. 4.2.1 Global RNA Vaccines Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global RNA Vaccines Sales by Type (2021-2032)
  8. 4.2.3 Global RNA Vaccines Sales Market Share by Type (2021-2032)
  9. 4.3 Global RNA Vaccines Revenue by Type
  10. 4.3.1 Global RNA Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global RNA Vaccines Revenue by Type (2021-2032)
  12. 4.3.3 Global RNA Vaccines Revenue Market Share by Type (2021-2032)
5 RNA Vaccines Market by Application
  1. 5.1 RNA Vaccines Application Introduction
  2. 5.1.1 Infectious Disease
  3. 5.1.2 Cancer
  4. 5.1.3 Other
  5. 5.2 Global RNA Vaccines Sales by Application
  6. 5.2.1 Global RNA Vaccines Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global RNA Vaccines Sales by Application (2021-2032)
  8. 5.2.3 Global RNA Vaccines Sales Market Share by Application (2021-2032)
  9. 5.3 Global RNA Vaccines Revenue by Application
  10. 5.3.1 Global RNA Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global RNA Vaccines Revenue by Application (2021-2032)
  12. 5.3.3 Global RNA Vaccines Revenue Market Share by Application (2021-2032)
6 Global RNA Vaccines Sales by Region
  1. 6.1 Global RNA Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global RNA Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global RNA Vaccines Sales by Region (2021-2026)
  4. 6.2.2 Global RNA Vaccines Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America RNA Vaccines Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe RNA Vaccines Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific RNA Vaccines Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa RNA Vaccines Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa RNA Vaccines Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global RNA Vaccines Revenue by Region
  1. 7.1 Global RNA Vaccines Revenue by Region
  2. 7.1.1 Global RNA Vaccines Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global RNA Vaccines Revenue by Region (2021-2026)
  4. 7.1.3 Global RNA Vaccines Revenue by Region (2027-2032)
  5. 7.1.4 Global RNA Vaccines Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America RNA Vaccines Revenue (2021-2032)
  8. 7.2.2 North America RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe RNA Vaccines Revenue (2021-2032)
  11. 7.3.2 Europe RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific RNA Vaccines Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa RNA Vaccines Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa RNA Vaccines Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Translate Bio
  2. 8.1.1 Translate Bio Company Information
  3. 8.1.2 Translate Bio Business Overview
  4. 8.1.3 Translate Bio RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Translate Bio RNA Vaccines Product Portfolio
  6. 8.1.5 Translate Bio Recent Developments
  7. 8.2 Tiba Biotechnology
  8. 8.2.1 Tiba Biotechnology Company Information
  9. 8.2.2 Tiba Biotechnology Business Overview
  10. 8.2.3 Tiba Biotechnology RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tiba Biotechnology RNA Vaccines Product Portfolio
  12. 8.2.5 Tiba Biotechnology Recent Developments
  13. 8.3 Sangamo Therapeutics
  14. 8.3.1 Sangamo Therapeutics Company Information
  15. 8.3.2 Sangamo Therapeutics Business Overview
  16. 8.3.3 Sangamo Therapeutics RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sangamo Therapeutics RNA Vaccines Product Portfolio
  18. 8.3.5 Sangamo Therapeutics Recent Developments
  19. 8.4 Moderna Therapeutics
  20. 8.4.1 Moderna Therapeutics Company Information
  21. 8.4.2 Moderna Therapeutics Business Overview
  22. 8.4.3 Moderna Therapeutics RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Moderna Therapeutics RNA Vaccines Product Portfolio
  24. 8.4.5 Moderna Therapeutics Recent Developments
  25. 8.5 In-Cell-Art
  26. 8.5.1 In-Cell-Art Company Information
  27. 8.5.2 In-Cell-Art Business Overview
  28. 8.5.3 In-Cell-Art RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 In-Cell-Art RNA Vaccines Product Portfolio
  30. 8.5.5 In-Cell-Art Recent Developments
  31. 8.6 Ethris
  32. 8.6.1 Ethris Company Information
  33. 8.6.2 Ethris Business Overview
  34. 8.6.3 Ethris RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ethris RNA Vaccines Product Portfolio
  36. 8.6.5 Ethris Recent Developments
  37. 8.7 eTheRNA
  38. 8.7.1 eTheRNA Company Information
  39. 8.7.2 eTheRNA Business Overview
  40. 8.7.3 eTheRNA RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 eTheRNA RNA Vaccines Product Portfolio
  42. 8.7.5 eTheRNA Recent Developments
  43. 8.8 CureVac
  44. 8.8.1 CureVac Company Information
  45. 8.8.2 CureVac Business Overview
  46. 8.8.3 CureVac RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 CureVac RNA Vaccines Product Portfolio
  48. 8.8.5 CureVac Recent Developments
  49. 8.9 BioNTech
  50. 8.9.1 BioNTech Company Information
  51. 8.9.2 BioNTech Business Overview
  52. 8.9.3 BioNTech RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioNTech RNA Vaccines Product Portfolio
  54. 8.9.5 BioNTech Recent Developments
  55. 8.10 Argos Therapeutics
  56. 8.10.1 Argos Therapeutics Company Information
  57. 8.10.2 Argos Therapeutics Business Overview
  58. 8.10.3 Argos Therapeutics RNA Vaccines Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Argos Therapeutics RNA Vaccines Product Portfolio
  60. 8.10.5 Argos Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 RNA Vaccines Value Chain Analysis
  2. 9.1.1 RNA Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 RNA Vaccines Production Mode & Process
  6. 9.2 RNA Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 RNA Vaccines Distributors
  9. 9.2.3 RNA Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst